Abstract | OBJECTIVE: METHODS: RESULTS: The overall survival has 61.5% (16/26). Of the 10 patients who failed primary treatment with EMA-CO, 9 (90%) had complete clinical responses to secondary chemotherapy with EMA-EP (3) or BEP (6), and 6 (60%) were placed into lasting remission. Of the 16 patients who failed primary treatment with methotrexate/ actinomycin D-based chemotherapy without etoposide, 10 (63%) had complete clinical responses to BEP (8), VIP (1) and ICE (1), and 10 (63%) achieved long-term remission. Adjuvant surgical procedures were performed on 15 patients as a component of their therapy; eight (73%) of 11 patients who underwent hysterectomy, five (62%) of eight patients who had pulmonary resections, and one patient who had wedge resection of resistant choriocarcinoma from the uterus survived. Survival was significantly influenced by both hCG level at the start of secondary therapy and sites of metastases. CONCLUSION:
|
Authors | John R Lurain, Bahareh Nejad |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 97
Issue 2
Pg. 618-23
(May 2005)
ISSN: 0090-8258 [Print] United States |
PMID | 15863169
(Publication Type: Journal Article, Review)
|
Chemical References |
- Dactinomycin
- Vincristine
- Etoposide
- Cyclophosphamide
- Cisplatin
- Methotrexate
|
Topics |
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, therapeutic use)
- Cisplatin
(administration & dosage)
- Cyclophosphamide
(administration & dosage)
- Dactinomycin
(administration & dosage)
- Etoposide
(administration & dosage)
- Female
- Gestational Trophoblastic Disease
(drug therapy)
- Humans
- Methotrexate
(administration & dosage)
- Pregnancy
- Treatment Outcome
- Vincristine
(administration & dosage)
|